Eloctate (efmoroctocog alfa) for hemophilia - Hemophilia News …
Dec 4, 2023 · Eloctate (efmoroctocog alfa) is an extended half-life therapy that’s approved to prevent and treat bleeds, including those occurring during surgery, in adults and children with hemophilia A. Its design allows it to last for a longer time in the body, thus requiring fewer doses. The therapy, which is administered via an intravenous or into-the ...
FDA Approves Hemgenix, 1st Gene Therapy for Hemophilia B
Nov 23, 2022 · by Margarida Maia, PhD November 23, 2022. The first gene therapy for adults with hemophilia B — branded as Hemgenix (etranacogene dezaparvovec) — has been approved by the U.S. Food and Drug Administration (FDA). Meant to be a one-time treatment, Hemgenix is expected to keep bleeding in check in the long term, while also allowing patients to ...
Adynovate (rurioctocog alfa pegol) for hemophilia
Oct 10, 2023 · Adynovate (antihemophilic factor, rurioctocog alfa pegol), sold as Adynovi in Europe, is a recombinant (lab-made) clotting factor VIII (FVIII) concentrate given as an intravenous (into-the-vein) injection to prevent and control bleeding in children and adults with hemophilia A. It is indicated for:
FEIBA (factor eight inhibitor bypassing activity) for hemophilia
Nov 9, 2023 · FEIBA (factor eight inhibitor bypassing activity), also known as activated prothrombin complex concentrate and anti-inhibitor coagulant complex, is a bypassing agent that’s approved to prevent or control bleeding episodes in people with hemophilia A and hemophilia B. It can be prescribed for patients with inhibitors, or neutralizing ...
Hemophilia symptoms: Early signs and complications - Hemophilia …
Oct 18, 2023 · Hemophilia is a rare disorder in which the blood doesn’t clot properly, resulting in the disease’s hallmark symptoms of bleeds — excessive bleeding that extends over a prolonged period of time — that in turn leads to other complications. Bleeds can occur outside the body (external bleeding) or within the body (internal bleeding). In …
Partners will work to further gene-editing treatment for …
Nov 10, 2023 · The partners will seek to advance a treatment involving gene editing — used to correct, add, or delete a DNA sequence — for the bleeding disorder. “We are thrilled to work with Novo Nordisk in the development of a potentially transformative gene editing treatment for a patient population in need of novel therapeutic approaches,” Pete Lutwyche, PhD, Genevant’s president and CEO, said ...
Replacement Therapy - Hemophilia News Today
Replacement therapy is one of the standard therapies used to treat hemophilia, a genetic disorder caused by the absence or defects in blood clotting factors.Hemophilia makes patients highly susceptible to bleeding due to a compromised cascade of clotting reactions that are necessary to “seal” injuries.. Replacement therapy involves supplying the missing clotting factor to …
Antifibrinolytics - Hemophilia News Today
Antifibrinolytics are medicines that promote blood clotting by preventing or slowing down a process called fibrinolysis, which is the break down of blood clots.Antifibrinolytics are used as a treatment for hemophilia, in surgical procedures to prevent excessive blood loss, and for heavy menstrual bleeding.. How antifibrinolytics work. Hemostasis is a …
FDA approves Beqvez gene therapy for adults with hemophilia B
Apr 26, 2024 · The therapy will be sold under the name Beqvez as it is in Canada, where it was approved for a similar indication this year. Marketed by Pfizer, Beqvez is under review in the European Union.It’s now the second approved gene therapy for hemophilia B in the U.S., following the clearance of Hemgenix in 2022 for certain adults with hemophilia B. ...
Hemophilia prognosis and life expectancy
A patient’s prognosis may vary somewhat depending on the severity of disease, but today even children with severe hemophilia are generally expected to have a normal life expectancy, if they are started on treatment early. Based on the same WFH estimates, the life expectancy for men already living with hemophilia is about 10 years shorter than ...